Related Experiment Video

Updated: Jan 24, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer

Eiki Ichihara1, Katsuyuki Hotta2, Kiichiro Ninomiya1

  • 1Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

Lung Cancer (Amsterdam, Netherlands)
|May 18, 2019
PubMed
Abstract

Insights

Re-administering osimertinib showed modest effectiveness in treating EGFR-mutant non-small-cell lung cancer (NSCLC) after resistance developed. This strategy offered tolerable toxicity, providing a potential option for patients with advanced NSCLC.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Osimertinib is a key treatment for EGFR-mutant non-small-cell lung cancer (NSCLC).
  • Acquired resistance to osimertinib limits treatment options.
  • Re-administration strategies are established for earlier EGFR TKIs but lack data for osimertinib.

Purpose of the Study:

  • To evaluate the efficacy of osimertinib re-administration in patients with acquired resistance.
  • To assess the clinical benefit and safety of re-challenging with osimertinib.

Main Methods:

  • Retrospective review of medical records of advanced NSCLC patients with EGFR mutations and T790M.
  • Analysis of patients who received osimertinib re-administration following acquired resistance.

Main Results:

  • Objective response rate (ORR) was 33% and disease control rate (DCR) was 73% in 15 evaluable patients.
  • Tumor shrinkage correlated with initial osimertinib response (r=0.585).
  • Median progression-free survival (PFS) was 4.1 months; toxicity was generally low (Grade 2 or lower).

Conclusions:

  • Re-administration of osimertinib demonstrates modest activity in EGFR-mutant NSCLC post-resistance.
  • The treatment is well-tolerated, suggesting it as a viable option.
  • Further investigation into re-administration strategies for osimertinib is warranted.
Keywords:
EGFR TKIEGFR mutationNon-small-cell lung cancerOsimertinibRe-administrationT790M

More Related Videos

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

367

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.4K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
5.7K
Resistance and Conductance01:25

Resistance and Conductance

A conductor's DC resistance at a given temperature is influenced by its resistivity, length, and cross-sectional area. Resistivity is an inherent property of the conductor material, with annealed copper serving as the international standard for measurement. For instance, the resistivity of hard-drawn aluminum at 20 degrees Celsius is 61% of the standard conductivity of annealed copper.
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
499
Equivalent Resistance01:16

Equivalent Resistance

In circuit analysis, situations often arise where resistors are neither in series nor parallel configurations. To tackle such scenarios, three-terminal equivalent networks like the wye (Y) (Figure 1 (a)) or tee (T) and delta (Δ) (Figure 1 (b)) or pi (π) networks come into play. These networks offer versatile solutions and are frequently encountered in various applications, including three-phase electrical systems, electrical filters, and matching networks.
948